NeoGenomics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St

May 05, 2025

NeoGenomics (NASDAQ:NEO) First Quarter 2025 Results

Key Financial Results

Revenue: US$168.0m (up 7.5% from 1Q 2024).
Net loss: US$25.9m (loss narrowed by 4.2% from 1Q 2024).
US$0.20 loss per share (improved from US$0.21 loss in 1Q 2024).

Our free stock report includes 2 warning signs investors should be aware of before investing in NeoGenomics. Read for free now.

earnings-and-revenue-growth — NasdaqCM:NEO Earnings and Revenue Growth May 5th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

NeoGenomics EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 3.4%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 23% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for NeoGenomics that you need to take into consideration.

If you're looking to trade NeoGenomics, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if NeoGenomics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.